Immunovia has announced final top-line data of the IMMray platform from a retrospective study in autoimmune diseases. The study showed that the IMMray biomarker platform could differentiate blood samples from patients with systemic lupus erythematosus (SLE) from other autoimmune diseases with 96% accuracy. This is an important first step to show the versatility and potential expansion of the IMMray technology to other indications. Immunovia's main focus continues to be pancreatic cancer in high-risk individuals and newly diagnosed diabetic patients. Additionally, the company has reported full year 2016 financial results. Cash at end 2016 was SEK259m; we have updated our valuation to SEK151 per share.
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
We are updating our valuation to SEK151 per share (vs SEK155 per share), mainly for the FY16 net cash position of SEK259m and our expenses forecast. The rest of our assumptions remain the same: we assume a penetration rate of 35% in patients at high risk of pancreatic cancer and 5% in newly diagnosed diabetic patients, targeting total peak sales of c SEK2.1bn in both groups. We look to include SLE in our valuation when Immunovia discloses its plans for this indication.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
http://www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn http://www.linkedin.com/company/edison-investment-research
Twitter http://www.twitter.com/Edison_Inv_Res
YouTube http://www.youtube.com/edisonitv
Google+ https://plus.google.com/105425025202328783163/posts
For more information please contact:
Juan Pedro Serrate
Edison Investment Research
+44-(0)20-3681-2534
Jonas Peciulis
Edison Investment Research
+44-(0)20-3077-5728
[email protected]
SOURCE Edison Investment Research
